Morbidly Obese Patients Exhibit Increased CYP2E1-Mediated Oxidation of Acetaminophen

Clinical Pharmacokinetics

Volumn 55, Issue 7, 2016, Pages 833-847

  van Rongen, Anne ^a,b   Välitalo, Pyry A J ^b   Peeters, Mariska Y M ^a   Boerma, Djamila ^a   Huisman, Fokko W ^a   van Ramshorst, Bert ^a   van Dongen, Eric P A ^a   van den Anker, Johannes N ^c,d,e   Knibbe, Catherijne A J ^a,b  

^a ST ANTONIUS HOSPITAL   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

^c CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^d UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^e SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAMINOPHEN CYSTEINE; ACETAMINOPHEN MERCAPTURATE; CYTOCHROME P450 2E1; DRUG METABOLITE; PARACETAMOL; PARACETAMOL GLUCURONIDE; PARACETAMOL SULFATE; UNCLASSIFIED DRUG; CYSTEINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CHEMICAL MODIFICATION; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; DRUG OXIDATION; ENZYME ACTIVITY; FEMALE; GLUCURONIDATION; HUMAN; LEAN BODY WEIGHT; LIVER FUNCTION; LIVER FUNCTION TEST; MALE; MORBID OBESITY; PLASMA CONCENTRATION-TIME CURVE; POSTOPERATIVE PAIN; PRIORITY JOURNAL; SULPHATION; ADOLESCENT; ANALOGS AND DERIVATIVES; BIOLOGICAL MODEL; BODY MASS; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY; YOUNG ADULT;

ACETAMINOPHEN; ADOLESCENT; ADULT; AREA UNDER CURVE; BODY MASS INDEX; CYSTEINE; CYTOCHROME P-450 CYP2E1; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; OBESITY, MORBID; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84955564842     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-015-0357-0     Document Type: Article

References (37)

1. Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384(9945):766–81.
2. Saurabh S, Smith JK, Pedersen M, Jose P, Nau P, Samuel I. Scheduled intravenous acetaminophen reduces postoperative narcotic analgesic demand and requirement after laparoscopic Roux-en-Y gastric bypass. Surg Obes Relat Dis. 2015;11(2):424–30.
3. Prescott LF. Kinetics and metabolism of paracetamol and phenacetin. Br J Clin Pharmacol. 1980;10(Suppl 2)(221):291S–8S.
4. Clements JA, Critchley JA, Prescott LF. The role of sulphate conjugation in the metabolism and disposition of oral and intravenous paracetamol in man. Br J Clin Pharmacol. 1984;18(4):481–5.
5. Critchley JA, Nimmo GR, Gregson CA, Woolhouse NM, Prescott LF. Inter-subject and ethnic differences in paracetamol metabolism. Br J Clin Pharmacol. 1986;22(6):649–57.
6. Rumack BH. Acetaminophen hepatotoxicity: the first 35 years. J Toxicol Clin Toxicol. 2002;40(208):3–20.
7. Park JM, Lin YS, Calamia JC, Thummel KE, Slattery JT, Kalhorn TF, et al. Transiently altered acetaminophen metabolism after liver transplantation. Clin Pharmacol Ther. 2003;73(209):545–53.
8. Manyike PT, Kharasch ED, Kalhorn TF, Slattery JT. Contribution of CYP2E1 and CYP3A to acetaminophen reactive metabolite formation. Clin Pharmacol Ther. 2000;67(206):275–82.
9. Chun LJ, Tong MJ, Busuttil RW, Hiatt JR. Acetaminophen hepatotoxicity and acute liver failure. J Clin Gastroenterol. 2009;43(207):342–9.
10. Forrest JA, Clements JA, Prescott LF. Clinical pharmacokinetics of paracetamol. Clin Pharmacokinet. 1982;7(2):93–107.
11. Michaut A, Moreau C, Robin MA, Fromenty B. Acetaminophen-induced liver injury in obesity and nonalcoholic fatty liver disease. Liver Int. 2014;34(7):e171–9.
12. Larson AM, Polson J, Fontana RJ, Davern TJ, Lalani E, Hynan LS, et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology. 2005;42(6):1364–72.
13. Abernethy DR, Divoll M, Greenblatt DJ, Ameer B. Obesity, sex, and acetaminophen disposition. Clin Pharmacol Ther. 1982;31(203):783–90.
14. Abernethy DR, Greenblatt DJ, Divoll M, Shader RI. Enhanced glucuronide conjugation of drugs in obesity: studies of lorazepam, oxazepam, and acetaminophen. J Lab Clin Med. 1983;101(213):873–80.
15. Brill MJE, Diepstraten J, van Rongen A, van Kralingen S, van den Anker JN, Knibbe CAJ. Impact of obesity on drug metabolism and elimination in adults and children. Clin Pharmacokinet. 2012;51(223):277–304.
16. Barshop NJ, Capparelli EV, Sirlin CB, Schwimmer JB, Lavine JE. Acetaminophen pharmacokinetics in children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr. 2011;52(175):198–202.
17. Bell LN, Temm CJ, Saxena R, Vuppalanchi R, Schauer P, Rabinovitz M, et al. Bariatric surgery-induced weight loss reduces hepatic lipid peroxidation levels and affects hepatic cytochrome P-450 protein content. Ann Surg. 2010;251(243):1041–8.
18. Chtioui H, Semela D, Ledermann M, Zimmermann A, Dufour JF. Expression and activity of the cytochrome P450 2E1 in patients with nonalcoholic steatosis and steatohepatitis. Liver Int. 2007;27(6):764–71.
19. Varela NM, Quinones LA, Orellana M, Poniachik J, Csendes A, Smok G, et al. Study of cytochrome P450 2E1 and its allele variants in liver injury of nondiabetic, nonalcoholic steatohepatitis obese women. Biol Res. 2008;41(1):81–92.
20. Chaudhary IP, Tuntaterdtum S, McNamara PJ, Robertson LW, Blouin RA. Effect of genetic obesity and phenobarbital treatment on the hepatic conjugation pathways. J Pharmacol Exp Ther. 1993;265(216):1333–8.
21. Corcoran GB, Wong BK, Shum L, Galinsky RE. Acetaminophen sulfation deficit in obese rats overfed an energy-dense cafeteria diet. Endocr Res. 1987;13(214):101–21.
22. Wong BK, Ernest U SW, Corcoran GB. An overfed rat model that reproduces acetaminophen disposition in obese humans. Drug Metab Dispos. 1986;14(238):674–9.
23. Hardwick RN, Ferreira DW, More VR, Lake AD, Lu Z, Manautou JE, et al. Altered UDP-glucuronosyltransferase and sulfotransferase expression and function during progressive stages of human nonalcoholic fatty liver disease. Drug Metab Dispos. 2013;41(3):554–61.
24. Aubert J, Begriche K, Knockaert L, Robin MA, Fromenty B. Increased expression of cytochrome P450 2E1 in nonalcoholic fatty liver disease: mechanisms and pathophysiological role. Clin Res Hepatol Gastroenterol. 2011;35(242):630–7.
25. Cook SF, King AD, van den Anker JN, Wilkins DG. Simultaneous quantification of acetaminophen and five acetaminophen metabolites in human plasma and urine by high-performance liquid chromatography–electrospray ionization–tandem mass spectrometry: method validation and application to a neonatal pharmacokinetic study. J Chromatogr B. 2015;1007:30–42.
26. R Development Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2008.
27. Beal S, Sheiner LB, Boeckmann A, Bauer RJ. NONMEM user’s guides (1989–2009). Ellicott City: Icon Development Solutions; 2009.
28. Keizer RJ, Karlsson MO, Hooker A. Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and Xpose. CPT Pharmacometrics Syst Pharmacol. 2013;2(43):e50.
29. Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001;28(39):481–504.
30. Byon W, Fletcher CV, Brundage RC. Impact of censoring data below an arbitrary quantification limit on structural model misspecification. J Pharmacokinet Pharmacodyn. 2008;35(40):101–16.
31. Owens KH, Murphy PG, Medlicott NJ, Kennedy J, Zacharias M, Curran N, et al. Population pharmacokinetics of intravenous acetaminophen and its metabolites in major surgical patients. J Pharmacokinet Pharmacodyn. 2014;41(3):211–21.
32. Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. Quantification of lean bodyweight. Clin Pharmacokinet. 2005;44(31):1051–65.
33. Emery MG, Fisher JM, Chien JY, Kharasch ED, Dellinger EP, Kowdley KV, et al. CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease. Hepatology. 2003;38(174):428–35.
34. O’Shea D, Davis SN, Kim RB, Wilkinson GR. Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: a putative probe of CYP2E1 activity. Clin Pharmacol Ther. 1994;56(222):359–67.
35. Ferslew BC, Johnston CK, Tsakalozou E, Bridges AS, Paine MF, Jia W, et al. Altered morphine glucuronide and bile acid disposition in patients with nonalcoholic steatohepatitis. Clin Pharmacol Ther. 2015;97(4):419–27.
36. Lloret Linares C, Decleves X, Oppert JM, Basdevant A, Clement K, Bardin C, et al. Pharmacology of morphine in obese patients: clinical implications. Clin Pharmacokinet. 2009;48(10):635–51.
37. Canet MJ, Merrell MD, Hardwick RN, Bataille AM, Campion SN, Ferreira DW, et al. Altered regulation of hepatic efflux transporters disrupts acetaminophen disposition in pediatric nonalcoholic steatohepatitis. Drug Metab Dispos. 2015;43(6):829–35.